Seeking Alpha

Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's...

Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's reiterated guidance following the Revlimid setback.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector